Several other equities analysts have also recently commented on the stock. Zacks Investment Research cut shares of Zynerba Pharmaceuticals from a buy rating to a hold rating in a research report on Saturday, May 11th. ValuEngine lowered shares of Zumiez from a hold rating to a sell rating in a research report on Tuesday, July 2nd.
Shares of SLP stock opened at $32.14 on Tuesday. The stock has a market cap of $547.68 million, a PE ratio of 71.00 and a beta of -0.38. Simulations Plus has a twelve month low of $16.79 and a twelve month high of $32.85. The stock has a fifty day moving average price of $27.19.
Simulations Plus (NASDAQ:SLP) last announced its quarterly earnings data on Wednesday, July 10th. The technology company reported $0.16 EPS for the quarter, topping the Zacks’ consensus estimate of $0.14 by $0.02. The firm had revenue of $9.94 million for the quarter, compared to the consensus estimate of $9.85 million. Simulations Plus had a return on equity of 23.48% and a net margin of 24.09%. On average, equities analysts anticipate that Simulations Plus will post 0.44 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, August 1st. Stockholders of record on Thursday, July 25th will be paid a $0.06 dividend. The ex-dividend date is Wednesday, July 24th. This represents a $0.24 annualized dividend and a dividend yield of 0.75%. Simulations Plus’s dividend payout ratio is currently 48.00%.
In other news, Director Walter S. Woltosz sold 18,500 shares of the company’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $25.67, for a total value of $474,895.00. Following the completion of the sale, the director now owns 5,178,083 shares in the company, valued at approximately $132,921,390.61. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 31.57% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Advisor Group Inc. boosted its holdings in shares of Simulations Plus by 156.9% in the 4th quarter. Advisor Group Inc. now owns 2,112 shares of the technology company’s stock worth $42,000 after buying an additional 1,290 shares during the last quarter. BNP Paribas Arbitrage SA lifted its holdings in Simulations Plus by 59,875.0% during the first quarter. BNP Paribas Arbitrage SA now owns 2,399 shares of the technology company’s stock valued at $51,000 after purchasing an additional 2,395 shares during the last quarter. Metropolitan Life Insurance Co. NY purchased a new stake in Simulations Plus during the fourth quarter valued at about $79,000. MetLife Investment Advisors LLC purchased a new stake in Simulations Plus during the fourth quarter valued at about $108,000. Finally, Bank of America Corp DE lifted its holdings in Simulations Plus by 65.7% during the fourth quarter. Bank of America Corp DE now owns 8,754 shares of the technology company’s stock valued at $174,000 after purchasing an additional 3,471 shares during the last quarter. Hedge funds and other institutional investors own 41.28% of the company’s stock.
Simulations Plus Company Profile
Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation, and machine-learning-based prediction of properties of molecules from their structure worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments that measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.